Tesamorelin in India | Prime Peptide

Q: What is Tesamorelin?

{"type"=>"root", "children"=>[{"type"=>"paragraph", "children"=>[{"type"=>"text", "value"=>"Tesamorelin is a synthetic analogue of human growth hormone-releasing hormone, also called GHRH or growth hormone-releasing factor. Research has examined how it influences endogenous growth hormone secretion and downstream IGF-1 concentrations."}]}]}

Q: Which receptor pathway is studied with Tesamorelin?

{"type"=>"root", "children"=>[{"type"=>"paragraph", "children"=>[{"type"=>"text", "value"=>"Tesamorelin is studied primarily in relation to the growth hormone-releasing hormone receptor, or GHRHR. This receptor is expressed on pituitary somatotroph cells and mediates signaling that supports endogenous growth hormone secretion."}]}]}

Q: How does Tesamorelin affect GH and IGF-1 signaling in research?

{"type"=>"root", "children"=>[{"type"=>"paragraph", "children"=>[{"type"=>"text", "value"=>"Published studies report that tesamorelin can increase basal and pulsatile endogenous growth hormone secretion. Because growth hormone influences IGF-1 production, increases in circulating IGF-1 have also been measured in tesamorelin studies."}]}]}

Q: What evidence supports the Tesamorelin research summary?

{"type"=>"root", "children"=>[{"type"=>"paragraph", "children"=>[{"type"=>"text", "value"=>"The research summary is supported by controlled human studies of GH pulsatility, population pharmacokinetic and pharmacodynamic modeling of GH and IGF-1, and pooled randomized Phase 3 trial data. The linked citations provide the study designs, populations, endpoints, and limitations."}]}]}

Q: What has Tesamorelin been studied for in clinical research?

{"type"=>"root", "children"=>[{"type"=>"paragraph", "children"=>[{"type"=>"text", "value"=>"Clinical research has examined tesamorelin in relation to endogenous GH pulsatility, IGF-1 concentrations, pharmacokinetics, pharmacodynamics, metabolic measurements, and visceral adipose tissue in defined study populations. Findings should be interpreted within each study's design and population and are not general instructions for personal use."}]}]}

PRODUCT OVERVIEW

What is Tesamorelin?

Tesamorelin is a stabilized growth-hormone-releasing hormone analogue used in laboratory research involving GHRH-receptor signaling, pituitary growth-hormone release, endocrine response, and peptide stability.

Its 44-amino-acid structure supports comparative studies of GHRH analogues, receptor activation, downstream signaling, and time-dependent hormone-release models.

Purity≥99%

Molecular Weight5136 g/mol

SequenceYADAIFTNSYRKVLGQLSARKLLQDIMSRQQGESNQERGARARL

StorageStore refrigerated at 2–8°C

FormLyophilized powder

Research UseFor in-vitro laboratory research only

Research mechanism Product-specific pathway illustration

RESEARCH AREAS

Tesamorelin Potential Use Cases

Product-specific research applications associated with Prime Peptide Tesamorelin.

GHRH-receptor signaling research

Pituitary response studies

Growth-hormone release models

Endocrine pathway assays

Peptide stability comparisons

Time-course signaling studies

KEY BENEFITS

Tesamorelin Research Highlights

Key research-oriented characteristics connected to Prime Peptide Tesamorelin.

Stabilized GHRH analogue
Defined 44-amino-acid sequence
Useful for receptor-response comparisons
Suitable for endocrine time-course models

SPECIFICATIONS

Tesamorelin Molecular Data

Molecular specifications for Prime Peptide Tesamorelin
Molecular Formula	C221H366N72O67S
Molecular Weight	5136 g/mol
Purity	≥99%
Appearance	White lyophilized powder
Solubility	Water-soluble
Storage	Store refrigerated at 2–8°C
Research Use	For in-vitro laboratory research only

3D Structure · Representative Model

BIOLOGICAL & MOLECULAR TARGETS

Tesamorelin Research Targets

Growth hormone-releasing hormone receptor

GHRHR

G protein-coupled receptor

A G protein-coupled receptor on pituitary somatotroph cells that mediates growth hormone-releasing hormone signaling and supports endogenous growth hormone secretion.

View reference ↗

SCIENTIFIC SOURCES

Tesamorelin Citations & References

Effects of a growth hormone-releasing hormone analog on endogenous GH pulsatility and insulin sensitivity in healthy men

Journal of Clinical Endocrinology & Metabolism 2011

A controlled study in 13 healthy men found that two weeks of tesamorelin increased basal and pulsatile growth hormone secretion and increased IGF-I. The study assessed insulin sensitivity using a euglycemic hyperinsulinemic clamp.

Read publication →

Population pharmacokinetic and pharmacodynamic analysis of tesamorelin in HIV-infected patients and healthy subjects

Journal of Pharmacokinetics and Pharmacodynamics 2015

This population PK/PD analysis characterized the time course of growth hormone and IGF-1 after repeated tesamorelin exposure in Phase I studies and developed a sequential model describing these pharmacodynamic markers.

Read publication →

Effects of tesamorelin (TH9507), a growth hormone-releasing factor analog, in human immunodeficiency virus-infected patients with excess abdominal fat: a pooled analysis of two multicenter, double-blind placebo-controlled phase 3 trials with safety extension data

Journal of Clinical Endocrinology & Metabolism 2010

A pooled analysis of two randomized Phase 3 studies involving 806 antiretroviral-treated participants examined tesamorelin over 26 weeks with a 26-week extension, including changes in visceral adipose tissue, IGF-I, metabolic measures, and safety.

Read publication →

TERMINOLOGY

Tesamorelin Glossary

Tesamorelin — A synthetic analogue of human growth hormone-releasing hormone studied for its effects on endogenous growth hormone pulsatility and insulin-like growth factor 1.

Also known as: TH9507, GHRH(1-44) analogue, Growth hormone-releasing factor analogue Source ↗

Growth hormone-releasing hormone — A hypothalamic peptide hormone that signals through GHRHR on pituitary somatotroph cells to stimulate growth hormone synthesis and secretion.

Growth hormone-releasing hormone, abbreviated GHRH, is a hypothalamic signaling peptide that binds the GHRH receptor on pituitary somatotroph cells. Receptor activation stimulates cAMP-dependent signaling and growth-hormone release.

Also known as: GHRH, Growth hormone-releasing factor, GRF Source ↗

Growth hormone-releasing hormone receptor — The receptor that mediates growth hormone-releasing hormone signaling at pituitary somatotroph cells and participates in regulation of endogenous growth hormone secretion.

Also known as: GHRHR, GHRH receptor Source ↗

Insulin-like growth factor 1 — A peptide growth factor whose circulating concentration is influenced by growth hormone signaling and is commonly measured in studies of the GH–IGF-1 axis.

Also known as: IGF-1, IGF-I, Somatomedin C Source ↗

COMMON RESEARCH QUESTIONS

Tesamorelin FAQ

What is Tesamorelin?

Tesamorelin is a synthetic analogue of human growth hormone-releasing hormone, also called GHRH or growth hormone-releasing factor. Research has examined how it influences endogenous growth hormone secretion and downstream IGF-1 concentrations.

Which receptor pathway is studied with Tesamorelin?

Tesamorelin is studied primarily in relation to the growth hormone-releasing hormone receptor, or GHRHR. This receptor is expressed on pituitary somatotroph cells and mediates signaling that supports endogenous growth hormone secretion.

How does Tesamorelin affect GH and IGF-1 signaling in research?

Published studies report that tesamorelin can increase basal and pulsatile endogenous growth hormone secretion. Because growth hormone influences IGF-1 production, increases in circulating IGF-1 have also been measured in tesamorelin studies.

What evidence supports the Tesamorelin research summary?

The research summary is supported by controlled human studies of GH pulsatility, population pharmacokinetic and pharmacodynamic modeling of GH and IGF-1, and pooled randomized Phase 3 trial data. The linked citations provide the study designs, populations, endpoints, and limitations.

What has Tesamorelin been studied for in clinical research?

Clinical research has examined tesamorelin in relation to endogenous GH pulsatility, IGF-1 concentrations, pharmacokinetics, pharmacodynamics, metabolic measurements, and visceral adipose tissue in defined study populations. Findings should be interpreted within each study's design and population and are not general instructions for personal use.